Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group

Marine Sroussi, Reza Elaidi, Aude Fléchon, Marianne Lorcet, Delphine Borchiellini, Magalie P. Tardy, Gwenaelle Gravis, Mathilde Guérin, Brigitte Laguerre, Florian Estrade, Rémi Delva, Phillipe Barthélémy, Yohann Loriot, Pernelle Lavaud, Thierry Lebret, Yann Neuzillet, Nicolas Penel, Nadine Houede, Damien Pouessel, Benoit RousseauElodie Mussat, Marine Gross-Goupil, Stéphane Culine, Hélène Gauthier, Aurélien Gobert, Morgan Roupret, Olivier Huillard, Sophie Tartas, Camélia Radulescu, Yves Allory, Stéphane Oudard

    Research output: Contribution to journalArticlepeer-review

    16 Citations (Scopus)

    Abstract

    Neuroendocrine carcinoma of the urinary bladder (NCUB) is a rare and heterogeneous disease, with scarce reported data available. The present retrospective study included 236 patients treated for NCUB. The median overall survival was 36 months for stage I/II, 26 months for stage IIIA, 16 months for stage IIIB, and 13 months for stage IVA/IVB. Disease-free survival was associated with overall survival.

    Original languageEnglish
    Pages (from-to)295-303.e3
    JournalClinical Genitourinary Cancer
    Volume18
    Issue number4
    DOIs
    Publication statusPublished - 1 Aug 2020

    Keywords

    • Chemotherapy
    • French GETUG consortium
    • Heterogeneity
    • Outcomes
    • Small cell bladder cancer

    Cite this